There is one clinical trial.
The global health emergency created by the rapid spread of the SARS-CoV-2 coronavirus has pushed healthcare services to face unprecedent challenges to properly manage COVID-19 severe and critical manifestations affecting a wide population in a short period of time. Clinicians are committed to do their best with a great uncertainty in this evolving crisis. Off label use of plenty of drugs has arisen the need for clinical trials to demonstrate their true role in the therapy. Based in unpublished experiences in China, Italy and Spain, intravenous IL-6 receptor inhibitors are now being tested in several trials but no data on subcutaneous formulations are available yet. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptors to inhibit IL-6 signalling, licensed in a subcutaneous route administration.
Description: Score ranges 1-7 Death; Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care Not hospitalizedMeasure: Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation Time: 7 days from enrolment
Description: Days from the date of enrolment to the date of dischargeMeasure: Duration of hospitalisation (days) Time: 30 days from enrolment
Description: Number of deathsMeasure: Death Time: 30 days from enrolment
Description: Time to become afebrile for a minimum period of 48 hours, without antipyreticsMeasure: Time to become afebrile (days) Time: 30 days from enrolment
Description: Days from enrolment to non-invasive mechanical ventilationMeasure: Time to non-invasive mechanical ventilation (days) Time: 30 days from enrolment
Description: Days from enrolment to invasive mechanical ventilationMeasure: Time to invasive mechanical ventilation (days) Time: 30 days from enrolment
Description: Days from enrolment to supplementary oxygen therapy withdrawalMeasure: Time to independence from supplementary oxygen therapy (days) Time: 30 days from enrolment
Description: Scale ranges 1-7: Death Hospitalized, with mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, with non-invasive mechanical ventilation, a mask with a reservoir or oxygen with high flow nasal goggles. Hospitalized with oxygen supplement Hospitalized, without oxygen supplement, but in need of continued medical care (related or not with COVID) Hospitalized, without oxygen supplement and without the need for continued medical care Not hospitalizedMeasure: Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation Time: 14 days from enrolment
Description: Number of adverse events and number of patients with adverse eventsMeasure: Incidence of serious and non-serious adverse events. Time: 30 days after enrolment
Description: Number of adverse reactions that requires discontinuation of any drug in the studyMeasure: Discontinuation due to adverse reactions Time: 30 days after enrolment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports